Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...
pharmaphorum2d
Lilly says Mounjaro launch is "viral in nature"
The launch of Mounjaro always raised the risk that it would cannibalise sales of Lilly's own GLP-1 agonist Trulicity (dulaglutide), which is competing head-to-head with Ozempic in the market ...
pharmaphorum2d
Lilly’s Mounjaro wins latest head-to-head battle in clinical trials of diabetes treatments
Mounjaro, manufactured by Lilly ... head-to-head battles began in 2012 with Lilly’s once-weekly injectable Trulicity taking on Novo Nordisk’s once-daily injectable Victoza — and the gamble ...
Cost of diabetes, obesity drugs often out of reach for low-income patients
While it may seem like everyone is taking Ozempic, not everyone can afford to. The high price of popular diabetes drugs ...
Briefing.com16d
Eli Lilly struggles to meet sky-high expectations as Q4 Mounjaro and Zepbound sales fall short (LLY)
The clear laggard has been Trulicity, a diabetes/weight loss drug that has been cannibalized by the surge in sales for Mounjaro and Zepbound. In Q3, Trulicity sales tumbled by 22% to $1.30 bln. The ...
The Motley Fool5d
Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
Roughly $15 billion of this total stems from just three drugs -- Mounjaro, Zepbound, and Trulicity. All of these are medications in Lilly's weight loss portfolio. However, another star performer ...